The first-line regimens of PD-1/PD-L1 inhibitors currently used in GC patients expressing PD-L1 are: (1) nivolumab plus chemotherapy (CPS ≥ 5%); (2) Sintilimab plus chemotherapy (China). Here, CD274 is linked to gastric cancer.